Oncology /Immuno-oncology Platform
Non-Human Primates Platform
Inflammation/Autoimmune Diseases Model
Metabolic/Liver/Cardiovascular Diseases Model
Antibody Screening Platform
There is a major obstacle to the evaluation of new human immunotherapies due to a lack of experimental models with a fully functional human immune system. Therefore, the development of humanized experimental models is an unmet need in immunotherapy research. As part of PharmaLegacy’s commitment to furthering immuno-oncology research, we have developed a humanized mouse model which harness the human immune system against human tumors.
The humanized mouse model can be used to provide:
• A microenvironment that mimics human immune cell responses
• An interaction between immune systems and tumor cells or tissues of human origin
• A cost-effective platform to evaluate the effectiveness of potential new drugs to modulate the immune system without putting patients at risk
We reconstitute NOG/NPG immunocompromised mice with a human hematopoietic system via engraftment of human cord blood CD34+ cells. The level of humanization is determined by human CD45+ cell ratio, which ranges from 40% to 60% with the majority of T and B cells in the peripheral blood after 16 weeks engraftment. Any mouse with >15% hCD45+ cells is considered as a valid model according to varies dosing studies. The CD34+ humanized mice have the longest research span of over a year without graft-versus-host disease.
Level of “humanization” (human CD45+ cells ratio) ranged between 40%-60%, with little variation between batches of hCD34+ HSC transplanted animals.
Level of human T cells reconstitution in peripheral blood increased continuously post hCD34+ HSC transplantation.
Cell Lines Validated
Cell Lines Under Validation
Lung Cancer Cell
Evaluating Oncolytic Virus in HCC827 Model